Roche Building $700M Drug Manufacturing Facility In North Carolina

Genentech, a member of the Roche Group, today announced plans to invest more than $700 million in a new 700,000-square-foot drug manufacturing facility in Holly Springs, North Carolina.

The company said the project will add more than 400 manufacturing jobs when the site is operational and more than 1,500 construction jobs during site development. The new facility will ultimately support Roche and Genentech’s future portfolio of next-generation obesity medicines and this initial investment could expand in the future based on business needs and the U.S. policy environment.

Roche and Genentech’s current U.S. footprint includes 13 manufacturing and 15 R&D sites across the company’s Pharmaceutical and Diagnostics Divisions and 25,000 employees in 24 sites across eight U.S. states.

“Our new facility near Raleigh, North Carolina, an established biopharmaceutical talent hub, will serve as an important new setting within our manufacturing network to help deliver on the promise of our company’s life-changing science and industry-leading pipeline. We are thrilled to establish this relationship with the city of Holly Springs, where we expect to have a positive impact on the local economy and community, as we have across the United States since we pioneered the biotech industry nearly 50 years ago," said Genentech CEO Ashley Magargee in a statement.